Skip to main content
WFH Hermes Main banner
Icon Legend
Program is subject to change
Pre-registration required
--------------------
General Plenary
General Plenary
Medical Plenary
Medical Plenary
Musculoskeletal Plenary
Musculoskeletal Plenary
Multidisciplinary Plenary
Multidisciplinary Plenary
Medical Track
Medical Track
Musculoskeletal Track
Musculoskeletal Track
Multidisciplinary Track
Multidisciplinary Track
WFH Session
WFH Session
Simultaneous interpretation in <b>SPANISH AND PORTUGUESE</b>
Simultaneous interpretation in SPANISH AND PORTUGUESE
CME credits
CME credits

Track: Medical

How to manage hemostasis during major surgery

Location: Pacifico
CE: 1

Medical Track CME credits

Learning Objectives:

  • Emicizumab - clinical trials: Emicizumab was approved as bleeding prophylaxis in patients with hemophilia A with and without inhibitors. Prospective trials to assess the efficacy as a surgical prophylaxis have not been completed, but we have trial data from the initial pivotal trials and post-marketing published experience that will be presented in the session to elicit the role of emicizumab in surgical prophylaxis.
  • Fitusiran - clinical trials: This is an exciting time for the bleeding disorders community as novel therapies are becoming available, with simpler subcutaneous administration, that not only promote hemostasis, prevent bleeds, and improve quality of life. Fitusiran is an investigational small interfering RNA (siRNA) therapeutic that knocks down antithrombin to promote hemostasis in individuals with hemophilia A and B, with and without inhibitors. In this presentation, we will discuss the use of fitusiran in the management of hemostasis during major surgery.
  • Emicizumab: The role of emicizumab as a haemostatic agent during surgery is not clearly defined. Most of the data is from the trials on emicizumab as a regular prophylaxis when some surgeries were also performed.  We present interim results from a prospective trial when patients with hemophilia A, with and without inhibitors, who were on emicizumab prophylaxis underwent elective major surgery with a predefined factor / bypass agent replacement protocol. 
  • Factor replacement in low resource countries: Surgical management of hemophilia is a new challenge for health care providers in LMICs. Compromised dosing secondary to inadequate clotting factor reserve may result in insufficient hemostatic control. On the other hand, massive clotting factor exposure during surgery in a previously unexposed patient may lead to the development of an inhibitor. In addition, the success of surgical procedures does not only depend on the appropriate replacement of the missing factor. Pre- and post-operative interventions, laboratory monitoring, care, and rehabilitation of the patient are also equally important. These issues will be highlighted in this talk.

Presentations:

  • 14:00 - 14:01 ART
    Chair

    Chair: Alok Srivastava, MD, FRACP, FRCPA, FRCP – Christian Medical College

  • 14:01 - 14:12 ART
    Emicizumab - clinical trials

    Speaker: Rebecca Kruse-Jarres, MD/MPH (she/her/hers) – Washington Center for Bleeding Disorders

  • 14:12 - 14:24 ART
    Fitusiran - clinical trials

    Speaker: Margaret V. Ragni, MD MPH (she/her/hers) – Division Hematology/ Oncology - University of Pittsburgh

  • 14:24 - 14:36 ART
    Emicizumab - a prospective clinical trial

    Speaker: Aby Abraham, MD, DM (he/him/his) – Christian Medical College Vellore

  • 14:36 - 14:48 ART
    Factor replacement in low resource countries

    Speaker: Bishesh Sharma Poudyal, MD (he/him/his) – Civil Service Hospital

  • 14:48 - 15:00 ART
    Discussion

    Chair: Alok Srivastava, MD, FRACP, FRCPA, FRCP – Christian Medical College